Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Quantification of circulating plasma cells at diagnosis can identify functional high risk multiple myeloma patients

View Full Paper
Ask AI
Bookmark
Share

Authors

NPNunziatina Laura ParrinelloSMSara MarinoGGGiuliana Giunta

Discussion

Loading...

Member takes

Overview

Quantification of circulating plasma cells predicts progression free survival in multiple myeloma, indicating better risk assessment.

Key Points

  • To evaluate the association of circulating plasma cells with risk stratification in patients with multiple myeloma.
  • Measured circulating plasma cells in peripheral blood of 164 patients with newly diagnosed MGUS, smoldering, and active multiple myeloma.
  • Used 8-color antibody panels for monoclonal plasma cell identification based on NGF methodology.
  • Performed multivariable analysis including parameters like lactate dehydrogenase levels and cytogenetics.
  • 83% of MGUS, 87% of smoldering, and 100% of active multiple myeloma patients had detectable circulating plasma cells.
  • Higher circulating plasma cell counts correlated with shorter progression free survival.
  • A cutoff of 0.02% circulating plasma cells was identified as an independent prognostic factor.

Cite This Study

Parrinello et al. (2025) studied this question.

synapsesocial.com/papers/693624d74fa91c937236d0b3https://doi.org/10.1182/blood-2025-2236
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Monoclonal and polyclonal circulating plasma cells (CPCs) are linked to disease spread in multiple myeloma2025
  2. 2Multiple myeloma with ≥1% circulating plasma cells in peripheral blood has a poor prognosis2025
  3. 3Circulating tumor plasma cells as an independent prognostic marker in newly diagnosed multiple myeloma: Clinical correlation and immunophenotypic insights2025
  4. 4Phenotypic evolution of circulating tumor plasma cells across MGUS, SMM and multiple myeloma2025
  5. 5Peripheral circulating myeloma cells accurately identify bone marrow MRD positivity in multiple myeloma patients receiving CAR T or autologous transplant2025